Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZYUS Life Sciences ( (TSE:ZYUS) ) has shared an announcement.
ZYUS Life Sciences has reached a significant milestone in its Phase 2a UTOPIA-1 trial, with 25% of patient enrollment completed. This trial evaluates the safety and preliminary efficacy of Trichomylin® softgel capsules for managing cancer-related pain. The company also announced it raised $1,250,000.50 in a non-brokered private placement, with no further tranches expected. ZYUS continues to explore additional financing opportunities to support its operations and strategic goals.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a clinical-stage life sciences company focused on developing and commercializing novel non-opioid pharmaceutical drug candidates for pain management. The company is currently conducting a Phase 2a clinical trial for its lead drug candidate, Trichomylin® softgel capsules, and aims to secure intellectual property protection and regulatory approval for its innovative therapies.
Average Trading Volume: 9,777
Technical Sentiment Signal: Sell
Current Market Cap: C$56.05M
Learn more about ZYUS stock on TipRanks’ Stock Analysis page.